Can WuXi AppTec’s Integrated Discovery Platform Power Oncology? WuXi AppTec’s integrated platform combines high-authority screening, pharmacology, and early assessment in a single end-to-end system.

SHANGHAI, SHANGHAI, CHINA, April 30, 2026 /EINPresswire.com/ -- Embedding Protection Into Drug Discovery’s Intangible ...

SHANGHAI, SHANGHAI, CHINA, April 30, 2026 /EINPresswire.com/ -- The development of new medicines increasingly depends ...

WuXi AppTec Co., a leading drug development and manufacturing services provider, saw its shares climb sharply on Tuesday ...

The central fair value estimate for WuXi AppTec has shifted from CN¥129.89 to CN¥137.83, putting a refreshed price target in focus for investors. Bullish and bearish analysts are reading this change ...

SAN DIEGO , CA, UNITED STATES, April 17, 2026 /EINPresswire.com/ -- In today’s life sciences landscape, the journey ...

SAN DIEGO , CA, UNITED STATES, April 14, 2026 /EINPresswire.com/ -- Since its foundation, WuXi AppTec has helped ...

Shares were up 15% at midday, reaching their highest level since December 2021 and on track for the largest single-day gain in 18 months. Its Shanghai-listed stock also rose 10% in the morning session ...

In moments of great uncertainty, sometimes the best approach is to just press on. That seems to be the strategy being embraced at CDMO WuXi AppTec, which issued a surprisingly upbeat 2024 forecast ...

WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first ...

ET Net News Agency, 29 April 2026] A direct manual trade of 635,700 shares of WUXI APPTEC (02359) was registered at 11:51a.m. The deal amounted to HK$88.65m, or at HK$139.45 per ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.